Human pelota homolog
AssigneeSmithKline Beecham Corporation
InventorsJeffrey Richard Jackson, Michael Joseph Hansbury
Life of this patent
Estimating the term…
Abstract
68772 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing 68772 polypeptides and polynucleotides in the design of protocols for the treatment of proliferative diseases such as leukemias, solid tumor cancers and metastases; chronic inflammatory proliferative diseases such as psoriasis and rheumatoid arthritis; proliferative cardiovascular diseases such as restenosis; prolifertive ocular disorders such as diabetic retinopathy; and benign hyperproliferative diseases such as hemangiomas, among others, and diagnostic assays for such conditions.
Claims20
An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the 68772 polypeptide of SEQ ID NO:2;
- or a nucleotide sequence complementary to said isolated polynucleotide.
A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a 68772 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
A 68772 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
An isolated 68772 polynucleotide comprising a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence having at least 80% identity to a nucleotide sequence encoding the 68772 polypeptide expressed by the cDNA insert deposited at the ATCC with Deposit Number ATCC 98438;
- and
- (b) a nucleotide sequence complementary to the nucleotide sequence of (a).
Dependencies are inferred from the claim text.